Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... months ahead of schedule ,, TSX Exchange Symbol: RVX ... Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the ... study of its lead drug RVX-208. "The completion of ... 5 months ahead of our original schedule, is a ... at the Cleveland Clinic. At this rate we could ...
(Date:2/8/2010)... clinical services team to present the critical processes that comprise ... departments. , ... Chicago, IL (PRWEB) ... Trial Operations (CTO) software, today announced that both Kristin Lucas ... selected to speak at the CBI Forecasting & Budgeting conference ...
(Date:2/8/2010)... SAN DIEGO , Feb. 8 ... that it has appointed William H. Rastetter Ph.D. to ... current Chairman and Chief Executive Officer of Receptos, Inc., ... "We are very pleased to welcome Bill Rastetter ... A. Mollica , Ph.D., Chairman of the Board of ...
(Date:2/8/2010)... is pleased to announce that it has hired Lisa Wichman and Sahar ... joins HDS as an Account Manager and will focus on key healthcare ... the Manager of that group Omaha, NE. , ... Foothill Ranch, CA ... pleased to announce the hiring of a new Account Manager and Manager ...
Breaking Biology Technology:Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference 2ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference 3ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference 4Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors 2Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions 2Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions 3
... 4 Imaging Diagnostic,Systems, Inc., (OTC Bulletin Board: IMDS), ... a new study evaluating the CTLM system as an,adjunct ... of Academic,Radiology. , ... Alexander Poellinger, MD, a radiologist at Charite Hospital in ...
... HARLEYSVILLE, Pa., Dec. 4 Raymond J. De Hont, Chairman and ... today that the Company,s Board of Directors, at their meeting on ... payable on March 12, 2009 to shareholders of record at the ... a 9.1% increase over the same period last year. , ...
... Pharma Limited ("Azur") today,announced that it has entered ... BPAX ) to acquire U.S. rights ... of estradiol which is,indicated for the treatment of ... was approved by the U.S. Food and Drug,Administration ...
Other Biology Technology:Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2Met-Pro Corporation Declares Quarterly Dividend 2Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2
(Date:2/7/2010)... health habits or behaviors, like cigarette smoking, may influence ... against HPV. , According to survey results on ... to vaccinate their daughters was not associated with one,s ... with certain behavioral factors of the parents. , Results ... of Cancer Epidemiology, Biomarkers & Prevention , a ...
(Date:2/7/2010)... per week increased the risk of developing pancreatic cancer ... consume soft drinks, according to a report in ... the American Association for Cancer Research. , Although ... deadly, and only 5 percent of people who are ... Ph.D., senior author on the study and associate professor ...
(Date:2/7/2010)... PAUL, Minn. Workers exposed to tricholorethylene (TCE), a ... auto parts, may be at a significantly higher risk ... today that will be presented at the American Academy ... to April 17, 2010. , "This is the first ... exposure to TCE may increase a person,s risk of ...
Breaking Biology News(10 mins):More smokers than non-smokers accept HPV vaccination for their daughters 2More smokers than non-smokers accept HPV vaccination for their daughters 3Soft drink consumption may increase risk of pancreatic cancer 2Elephant size loopholes sustain Thai ivory trade 8912 1Elephant size loopholes sustain Thai ivory trade 8912 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 1Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 3K State Veterinarian Says Although Exotic Pets Can Be Great Companions There Are Health Factors That Can Affect Both the Animal and Humans 49435 1K State Veterinarian Says Although Exotic Pets Can Be Great Companions There Are Health Factors That Can Affect Both the Animal and Humans 49435 2K State Veterinarian Says Although Exotic Pets Can Be Great Companions There Are Health Factors That Can Affect Both the Animal and Humans 49435 3
... MADISON, WI, OCTOBER 20, 2008 -- The widespread use of ... decades, with little knowledge of the long-term effects on the ... study show that samples taken from over 300 wells across ... contamination. The news is a result of a decadal long ...
... Fritz et al. have identified an amino acid switch ... such as tick-borne encephalitis virus (TBEV), yellow fever, and ... cells by being gobbled up into endosomes and fusing ... triggered by the endosome,s acidic environment. Low pH prompts ...
... -- Researchers are one step closer to finding a ... for TB tested at Saint Louis University appears likely ... disease than the one in current use. , "Not ... it induced a better immune response, which suggests it ...
Other Biology News:Pesticide concentrations decreasing 2Research identifies type of vaccine that holds promise in protecting against TB 2
... (Dual-Stage Quadrupole) Thermo Scientific (Part of Thermo ... instrumentation, introduces the latest product innovation for ... on the proven reliability and performance platform ... the DSQ II incorporates the new DynaMax ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... The ProteoSpin CBED Micro Kit provides a ... exchange and desalting of protein samples. The ... Norgens patented protein resin as an ion ... CaCl2,LiCl, CsCl have poor affinities for Norgens ...
... Pathway 435 is an affordable, compact ... and slides, providing a broad array ... rapidly acquires high-resolution images with high-performance ... computer-controlled excitation and emission filter changers, ...
Biology Products: